Table 2.
Overview of therapeutic interventions and clinical outcomes for patients with COVID-19 by severity at triage.
| No. (%) | ||||||
|---|---|---|---|---|---|---|
| Entire cohort (n = 98) |
Severity at triage | |||||
| Mild (n = 13) |
Moderate (n = 79) |
Severe (n = 3) |
N/A (n = 3) |
P-value | ||
| Therapeutic approach | ||||||
| Mechanical ventilation | 4 (4.1) | 0 (0) | 2 (2.5) | 2 (66.7) | 0 (0) | 0.01 |
| Glucocorticoid | 10 (10.2) | 0 (0) | 10 (12.7) | 0 (0) | 0 (0) | 0.66 |
| Chloroquine | 17 (17.3) | 1 (7.7) | 15 (19.0) | 0 (0) | 1 (33.3) | 0.54 |
| LPV/r | 12 (12.2) | 1 (7.7) | 11 (13.9) | 0 (0) | 0 (0) | 1.00 |
| IVIG | 13 (13.3) | 2 (15.4) | 9 (11.4) | 1 (33.3) | 1 (33.3) | 0.18 |
| Final severity stratification during hospitalization | <0.001 | |||||
| Mild | 8 (8.2) | 6 (46.2) | 1 (1.3) | 0 (0) | 1 (33.3) | |
| Moderate | 66 (67.3) | 5 (38.5) | 59 (74.7) | 0 (0) | 2 (66.7) | |
| Severe | 19 (19.4) | 2 (15.4) | 16 (20.3) | 1 (33.3) | 0 (0) | |
| Critical | 5 (5.1) | 0 (0) | 3 (3.8) | 2 (66.7) | 0 (0) | |
| Outcomes | ||||||
| Length of stay in hospital, days, IQR | 18.0 (14.8–25.3) | 20.0 (16.0–23.5) | 18.0 (15.0–26.0) | 19.0 (9.0–23.0) | 13.0 (11.0–19.0) | 0.54 |
| Died in hospital | 1 (1.0) | 0 (0) | 0 (0) | 1 (33.0) | 0 (0) | 0.06 |
| Discharged from hospital | 96 (98.0) | 13 (100) | 78 (98.7) | 2 (66.7) | 3 (100) | 0.16 |
| Days to negativity, IQRa | 8.0 (4.0-10.0) | 9 (3–12) | 8 (5–10) | 4 (4–9) | N/A | 0.64 |
COVID-19 coronavirus disease 2019, N/A not available, LPV/r lopinavir/ritonavir, IVIG intravenous immunoglobulin, IQR interquartile range.
aDuration from admission to the date that patients tested a second PCR negativity in throat or nasal swab specimen.